Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CCR6 | P51684 | 4/20 | 0.54 |
| ▸ | APEX1 | P27695 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | PKLR | P30613 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15904413 | 0.86 | ALDH1A1 (0.63) | EPHX2ALDH1A1LMNASMN1; SMN2ATM | |
| SCHEMBL4525391 | 0.84 | ALDH1A1 (0.64) | EPHX2ALDH1A1LMNASMN1; SMN2KDM4E | |
| SCHEMBL2285784 | 0.82 | ALDH1A1 (0.76) | EPHX2ALDH1A1LMNASMN1; SMN2ATM | |
| SCHEMBL4710924 | 0.81 | ALDH1A1 (0.76) | ALDH1A1LMNASMN1; SMN2KDM4EGAA | |
| SCHEMBL4801328 | 0.81 | MEN1 (0.68) | ALDH1A1LMNASMN1; SMN2ATMKDM4E | |
| SCHEMBL13993549 | 0.81 | MEN1 (0.69) | EPHX2ALDH1A1LMNAGAACCR6 | |
| SCHEMBL6955039 | 0.81 | ALDH1A1 (0.68) | EPHX2ALDH1A1LMNASMN1; SMN2ATM | |
| SCHEMBL14421722 | 0.81 | EPHX2 (0.56) | EPHX2GAACCR6L3MBTL1PKM | |
| SCHEMBL2636523 | 0.81 | MAPT (0.70) | EPHX2ALDH1A1LMNASMN1; SMN2ATM | |
| SCHEMBL6519601 | 0.81 | ALDH1A1 (0.72) | EPHX2ALDH1A1LMNASMN1; SMN2ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306048-A1 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306048-A1 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HSD11B1, HSD3B1, CES1 | EPHX2 2010/4885ALDH1A1 46/4885LMNA 3211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.